Barinthus Bio presents interim Phase 2b HBV003 and Phase 2a AB-729-202 data for VTP-300 in chronic HBV at AASLD

Barinthus Biotherapeutics plc.

In HBV003, 31% of participants with screening HBsAg ≤200 IU/mL had >1 log HBsAg reductions.
In AB-729-202, all VTP-300 treated patients maintained HBsAg <100 IU/mL through week 48; 60% maintained <10 IU/mL.
Seven HBV003 participants met criteria for NUC discontinuation; three discontinued NUC therapy.
No treatment-related serious adverse events were reported in either trial.
Data presented in collaboration with Arbutus Biopharma (ABUS) for imdusiran plus VTP-300 combination.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.